Strona główna・Stock List・Lantheus Holdings Inc

Lantheus Holdings Inc

Open

SectorHealthcare

100.1 -0.15

Buy Sell

Overview

Share price change

24h

Current

Min

99.98

Max

100.47

Key metrics
By Trading Economics
Income	75M 193M
Sales	11M 388M
P/E Sector Avg	24.156 56.597
EPS	1.32
Profit margin	49.834
Employees	1,193
EBITDA	-69M 115M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+5.14% upside

Dividends
By Acuity
Next Earnings	5 lis 2026

Market Stats
By TradingEconomics
Market Cap	2.5M 6.6B
Previous open	100.25
Previous close	100.1

News Sentiment

By Acuity

60%

40%

273 / 339 Ranking in Healthcare

Lantheus Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 wrz 2026, 19:46 UTC

Lantheus Holdings Inc. shares are lower today, with no specific news identified. Price action remains flat amid broader market conditions following CPI data release.

10 wrz 2026, 19:16 UTC

Lantheus Holdings Inc. shares are lower today, with no specific news identified. The stock has traded within a routine range since Wednesday's close.

3 wrz 2026, 20:07 UTC

Lantheus Holdings Inc shares are higher during Thursday's session, reflecting a modest gain since Wednesday's close amid routine trading fluctuations.

1 wrz 2026, 19:16 UTC

Lantheus Holdings Inc. shares are trading roughly flat amid no specific news, reflecting minor changes since Monday's close.

20 sie 2026, 19:36 UTC

Lantheus Holdings Inc. shares are lower, impacted by a decline in the Health Care Supplies sub-sector. The asset remains near its one-month range low.

19 sie 2026, 23:26 UTC

Lantheus Holdings Inc. is seeing modest gains in after-market trading, with no specific news identified to explain the price movement.

13 sie 2026, 20:06 UTC

Lantheus Holdings Inc. is moving higher amid overall market gains, despite no specific company news to explain the advance.

12 sie 2026, 23:36 UTC

Lantheus Holdings Inc. shares declined in after-market trading, remaining below their 20-day moving average amid recent inflation data influencing investor sentiment.

3 sie 2026, 19:56 UTC

Social Media

News

Event

Lantheus Holdings Inc. to be acquired by Curium for up to $8 billion, offering $102.50 per share plus contingent value rights. Shares rise amid merger news.

31 lip 2026, 22:01 UTC

Lantheus Holdings Inc shares are lower in after-market hours amid weak trading conditions, remaining below the 20-day moving average and near a one-month low.

30 lip 2026, 17:31 UTC

Lantheus Holdings Inc is higher during Thursday's session, driven by overall market momentum, despite earlier downward pressure. The S&P 500 Index is also advancing.

29 lip 2026, 21:42 UTC

Lantheus Holdings Inc is trading lower in after-market hours, influenced by a decline in the broader market and rising oil prices amid geopolitical tensions.

28 lip 2026, 19:42 UTC

Social Media

Lantheus Holdings is in talks for a $7 billion acquisition by Curium, with shares declining despite the news and reaching a session low earlier.

27 lip 2026, 22:51 UTC

News

Lantheus Holdings is in talks for a $7 billion acquisition of Curium. Shares are trading lower in after-market hours amid deal evaluations.

24 lip 2026, 22:01 UTC

Lantheus Holdings Inc is trading lower in after-market hours, moving toward the lower end of its one-month trading range. No specific news was identified.

23 lip 2026, 23:02 UTC

Lantheus Holdings Inc. shares are lower in after-market trading, continuing a downward trend since Thursday's close, remaining below the 20-day moving average.

22 lip 2026, 19:06 UTC

Lantheus Holdings Inc shares are lower today, continuing a decline since Tuesday's close. Broader market sentiment is impacted by rising crude oil prices.

21 lip 2026, 22:46 UTC

Lantheus Holdings Inc shares are trading higher in after-market hours, supported by a broader market rebound, particularly in the tech sector.

20 lip 2026, 19:46 UTC

Lantheus Holdings Inc. shares are lower today, declining amid rising oil prices above $90 per barrel, contributing to inflationary pressures globally.

Peer Comparison

Price change

Lantheus Holdings Inc Forecast

Price Target

By TipRanks

5.14% upside

12 Months Forecast

Average 105.4 USD 5.14%

High 115 USD

Low 102.5 USD

Based on 10 Wall Street analysts offering 12 month price targets forLantheus Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Lantheus Holdings Inc - Dist in the past 3 months.

Sentiment

By Acuity

273 / 339 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.